Adherence and Clinical Correlates in Persons With HIV on TAF

Completed

Conditions studied: Hiv

In brief

This is an observational, 48-week, prospective study of PWH treated with TAF in which the investigators will compare TFV-DP concentrations in DBS in virologically suppressed vs. non-suppressed individuals and evaluate the utility of TFV-DP in DBS to predict future viremia. To accomplish this, the investigators will approach PWH currently taking TAF (which is being prescribed by a primary care physician) and who present to the clinic for regular HIV care and HIV VL assessment. Participants will complete up to 3 visits (at least 2 weeks apart) during the 48-week study follow-up period.

Key facts

Study ID

NCT05335590

Run by

University of Colorado, Denver

People needed

384

Starts

2022-04-25

Expected to finish

2026-05-04

Last updated by the study team

2026-05-06

Who can join

Age: 18 and older, up to 89. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Females or males with HIV (≥18 years), able to give informed consent and comply with study procedures who are having a blood draw as part of their regular clinical care.
• Being prescribed TAF-based ART >= 3 months.

You may not qualify if…

• For females, active pregnancy or intent to become pregnant.

Where it is running

• University of Colorado Health — Aurora, Colorado, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.